Glucocorticoid-induced osteoporosis (GIOP) leads to fractures in up to 40% of patients with
chronic glucocorticoid (GC) therapy when left untreated. GCs rapidly increase fracture risk …

Glucocorticoids have been available since the early 1950s and have since become an
integral part of the management of rheumatoid arthritis (RA). Due to their rapid effect …

Objective The negative effects of glucocorticoids on bone depend on dose and treatment
duration. However, it is unclear whether a safe dose exists, especially for patients with …

Objectives Clinical trials have shown a beneficial effect from biological disease-modifying
antirheumatic drugs (bDMARDs) on hand or axial bone loss in patients with rheumatoid …

We ascertained the fracture risk factors stratified by vertebral and non-vertebral sites in
rheumatoid arthritis (RA) females. Bone/muscle features, but not disease activity, were the …

Objectives To estimate the incidence of clinical fragility fractures in postmenopausal women
with rheumatoid arthritis (RA) and analyze risk factors for fracture. Methods Incidence of …

Objectives To provide an evidence base for clinical practice guidelines (CPG) for the
management of rheumatoid arthritis (RA) in older adults. Methods PubMed, Cochrane …

Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) such as
rheumatoid arthritis, connective tissue diseases, vasculitides and spondyloarthropathies are …

Based on current evidence the benefit–risk balance of low-dose glucocorticoids in
rheumatoid arthritis, and probably in other rheumatic diseases is generally favourable …

Bone mineral density (BMD) reduction and fragility fractures still represent a major source of
morbidity in rheumatoid arthritis (RA) patients, despite adequate control of the disease. An …